Intra-Cellular Therapies, Inc. (ITCI)

Trade ITCI now with
6/29/2020 8:28:32 AM Intra-Cellular Therapies Reports Positive Top-line Results From ITI-214 Phase I/II Study
4/2/2020 8:19:36 AM Intra-Cellular Therapies Begins Promotional Activities For CAPLYTA
3/23/2020 7:36:18 AM Intra-Cellular Therapies Announces Availability Of CAPLYTA For Adult Patients With Schizophrenia
1/7/2020 11:33:03 PM Intra-Cellular Therapies Prices Public Offering Of 10 Mln Shares At $29.50/Shr
12/23/2019 7:01:24 AM Intra-Cellular Therapies: FDA Approves CAPLYTA For The Treatment Of Schizophrenia In Adults
7/8/2019 7:11:54 AM Intra-Cellular Therapies Announces Positive Top-line Results From Phase 3 Trial Of Lumateperone
7/2/2019 8:17:08 AM Intra-Cellular Therapies Appoints Karen Patruno Sheehy As SVP, Chief Compliance Officer
12/18/2018 8:43:04 AM Intra-Cellular Therapies: DMC Concluded That Study 201 Is Not Likely To Meet Primary Endpoint
10/17/2018 8:08:02 AM Intra-Cellular Therapies To Present Results From ITI-214 Phase 1/2 Clinical Trial In Patients With Parkinson’s Disease